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Supporting Statement: 
The development of MR-Linac, and the deployment of two such machines in London and 
Manchester, is an exciting development for the radiotherapy community generally, and in the 
UK. The physical and engineering advances that have made it possible, and the great potential 
of this technology, were well summarised in a recent review article in this journal. Nonetheless, 
the introduction of new and advanced technology in both radiology and radiotherapy is complex 
and risky. Careful consideration of, and attention to, these complexities can mitigate the risk, 
ensuring successful development and deployment of technological advances, with maximum 
benefits to patients. This commentary seeks to provide counterpoint, and provide the reader 
with a balanced view, by describing these complexities, and suggesting where further work is 
needed.  
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Abstract: 
 
MR-based image-guided radiotherapy via all-in-one MR treatment units (MR-linacs) is one of the 
hottest topics in contemporary radiotherapy research. By ingenious engineering solutions to 
complex physical problems, researchers have developed machines with the promise of superior 
image quality, and all the advantages this may confer. Benefits include better tumour 
visualisation, on-line adaptation and the potential for image biomarker-based personalised RT.  
However, it is important to remember that the technical challenges are real. In many instances 
they are skillfully managed rather than abolished, a point illustrated by the wide variety of MR-
linac designs.  
 
The proposed benefits also deserve careful inspection. Better visibility of the primary tumour on 
an IG scan cannot be bad, but does not automatically equate to better IG, which often depends 
on a more generalised match to daily anatomy. MR-linac will undoubtedly be a rich milieu in 
which to search for imaging biomarkers, but these will need to be carefully validated, and similar 
work with CT-based biomarkers using existing, cheaper, and more widely available hardware is 
currently ongoing. On-line adaptation is an attractive concept, but practicalities are complex, 
and more work is required to understand which patients will benefit from plan adaptation, and 
when.  
 
Finally, the issue of cost cannot be overlooked, nor can the research community’s 
responsibilities to global healthcare inequalities. MR-linac is an exciting and ingenious 
technology, which merits both investment and research. It may not, however, have the future to 
itself.  
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Full Text: 
 
The headline debate at this year’s ESTRO congress (2017) was entitled “this house believes that the 
future of radiotherapy will be proton-guided photons, not photon guided protons”, illustrating that 
the two ‘hottest’ topics in contemporary radiotherapy research are MRI-guided external beam 
radiotherapy – MR-linac – and proton beam therapy (PBT). An excellent overview of the theoretical 
advantages of MR-image guidance, and the capabilities of all-in-one MR-treatment units, was 
recently published in this journal.1 This paper eloquently and succinctly describes the physical and 
engineering challenges of MR-linac. It is clear both from the article and the papers cited that many of 
these challenges have now been solved, but it is interesting to note that the two major hardware 
manufacturers initially adopted diametrically opposed principles (cobalt vs. linear accelerator) in 
their approach to tackling them. In our view, this serves as a reminder that the physical limitations of 
MR-linac are real, and should not be ignored. In their introduction, Dr Pollard and colleagues quote 
Andre Agassi in saying that “Image is everything”, but at least in radiotherapy this may not be the 
whole story.  
 
The same introduction1 asserts that “the need to “see” the tumour is the basis of IGRT [image-guided 
radiotherapy]”, a notion we partially challenge. ‘Seeing the tumour’ begins at the time of planning. It 
is widely accepted that manual target volume segmentation is often the weakest link in the 
contemporary RT workflow, but this is mainly due to lacking consensus on target volume definition, 
inadequate training, poor availability of quality imaging for planning RT, and intrinsic limitations in 
diagnostic imaging, including MRI. In other words, inaccurate target volume delineation for planning 
is not caused by inadequate image guidance (IG) hardware. We suggest that the primary purpose of 
IGRT is actually to ensure that the planned dose-cube is delivered as accurately as possible to the 
anatomy of the day, a concept that includes the clinical target volume(s) (CTVs) and organs at risk 
(OARs), as well as the gross tumour volume (GTV) itself. To our knowledge there is no evidence as yet 
that photon-based IG techniques are inferior with regards to this specific endpoint. 
 
The authors rightly suggest that adapting treatment on the basis of imaging biomarkers (IMB’s) is an 
ultimate objective of MR-guided RT. On this subject however, we urge caution. As noted in an 
important recent consensus guideline for IMB studies, approximately 10,000 papers on IMB’s were 
published between 2004 and 2014, many of these in cancer.2 Embarrassingly few have ever been 
externally validated, and fewer still have changed practice. To paraphrase the conclusions of this 
paper, IMB’s have great potential to facilitate advances in oncology research and practice, but must 
first undergo rigorous scrutiny and validation. Furthermore, we challenge the idea that MR is the 
only IG modality that could be used for this purpose. Whilst MR datasets are obviously a rich 
environment in which to search for IMB's, it would be fallacious to assume that CT could not be used 
as well .3 
 
Dr Pollard and colleagues initially argue that the raison d’être of MR-IG is superior identification of 
target structures conferring more accurate image guidance, but subsequently infer that the potential 
for real-time tracking and modification of RT plans is what really sets MR-linac apart from its 
competitors. We agree that on-line plan adaptation is an exciting possibility, but have some 
reservations about the detail. Firstly, on-line segmentation of IG images and re-optimisation of dose 
plans relies on powerful deformable image registration (DIR). The accuracy of DIR varies depending 
on anatomical location, and uncertainties about how best to accumulate dose to organs changing 
size, shape and position on a daily basis remain. When added to the (admittedly small) uncertainties 
of dose calculation within a strong magnetic field, we are faced with the possibility that uncertainties 
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in reported differences between planned and accumulated dose may be of a similar magnitude to 
reported differences themselves.4,5 Even if we accept accumulated dose figures reported by our MR-
linac systems entirely at face value, the question of what to do with them remains. On-line Adaptive 
RT (ART) is an attractive notion, and will undoubtedly become more widespread in clinical practice 
over the next decade. However, there is growing consensus that not all patients will benefit from 
ART,6 or at least that such benefits will be difficult to quantify and measure. Furthermore, we don’t 
yet know which patients will benefit most from plan adaptation, or when is the best time to adapt. 
MR-IG and MR-linac clearly has a major role to play in answering these questions, but in our view this 
should be in the research space, rather than widespread clinical use. The coordinated and 
collaborative approach of the Philips-Elekta consortium gives reason for high hope in this regard.7  
 
These problems notwithstanding, there is the separate issue of throughput and resource. To our 
understanding, most current MR-linac workflows require clinician review and ‘sign off’ of daily 
segmentation as well as the decision to implement dose re-optimisation, and approval of the new 
plan. Despite significant (and elegant) automation, this workflow remains highly resource intensive, 
and would be impractical in achieving a high throughput of patients in many healthcare systems – 
not least the UK.  
 
This leads onto our next concern, which is, inevitably, one of cost. On the basis of manufacturer 
figures, we estimate that the cost of replacing sufficient operational linacs in the UK with MR-linac, in 
order to treat all prostate cancer patients with this technology, to be over £500 million. This is an 
eye-watering figure in the current economic climate, and the problem is not solely confined to the 
UK. Parallels with the PBT story in the USA are all too apparent. In 2007, Anthony Zeitmann 
presciently warned of an impending collision between the Titanic (the shiny new vanguard of high 
technology – PBT), and the Iceberg (the cold, hard, unyielding laws of economics).8 As predicted, 
American insurance companies in the US took note of the rapidly rising costs of radiation oncology 
treatment, and access to PBT for many tumours has been restricted, with predictable consequences.9 
A key reason for this was the lack of robust clinical data demonstrating clear benefit for the newer, 
more expensive technology. For MR-linac to succeed, we suggest that coordinated collaboration to 
generate this evidence must be a priority for the community.7 Such research need not only apply to 
MR-IG and MR-linac; there is much scope for research and development using existing X-ray based 
systems (especially if manufacturers can improve the quality of current IG-CT), and making the most 
of, or reaching the 'pareto-front' with, the equipment we already have may be a far more cost-
effective way of treating the majority of our patients.  
 
Our final point touches on the issue of global inequalities, a problem that is not unique to radiation 
oncology. It seems that we are following a path of ever-increasing investment into research on 
increasingly advanced technologies with scope to treat fewer and fewer people. Concurrent with 
this, there are still countries without a single functioning radiotherapy machine.10 Whilst the 
iniquities of this state of affairs are beyond the scope of this piece, its existence lends credence to 
the notion that we must do everything possible to optimize our use of the technologies that we 
already have, and to make them more widely available.11  
 
Dr Pollard’s article should be recommended reading for any young radiotherapist wishing to 
understand the benefits of MR-IG, and the potential it holds for the future. We agree that MR will 
play an important role in the future of IGRT. It may not be the whole answer, however, and we urge 
researchers in other areas not to down tools. We cannot side step the issue of cost, and it is 
imperative that we try to quantify the benefits these technologies confer to our patients. To 
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paraphrase another great tennis player - Arthur Ashe - we should start where we are, use what we 
have, and do what we can.12 
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